Evidence map›Paper›PMID 36711976›Full record

ArticlebioRxiv : the preprint server for biology2023

Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma.

Michael D Kinnaman, Simone Zaccaria, Alvin Makohon-Moore, Brian Arnold, Max Levine, Gunes Gundem, Juan E Arango Ossa, Dominik Glodzik, M Irene Rodríguez-Sánchez, Nancy Bouvier and 20 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 3 institutions in 2 countries.

Michael D KinnamanDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Simone ZaccariaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Alvin Makohon-MooreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brian ArnoldDepartment of Computer Science, Princeton University, Princeton, NJ, USA.
Max LevineDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gunes GundemDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Juan E Arango OssaDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dominik GlodzikDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
M Irene Rodríguez-SánchezDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nancy BouvierDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shanita LiDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emily StockfischDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marisa DuniganIntegrated Genomics Operation Core, Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cassidy CobbsIntegrated Genomics Operation Core, Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Umesh BhanotDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daoqi YouDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Katelyn MullenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jerry MelchorHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael V OrtizDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tara O'DonohueDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emily SlotkinDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Leonard H WexlerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Filemon S Dela CruzDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Meera HameedDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julia L Glade BenderDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William D TapDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul A MeyersDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elli PapaemmanuilDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew L KungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christine A Iacobuzio-DonahueHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USCancer Research UK · GBPrinceton University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Experimental evolution of pancreatic cancerR00CA229979 · NCI · HACKENSACK UNIVERSITY MEDICAL CENTER · PI MAKOHON-MOORE, ALVIN · 2022 to 2024
$747k
NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA229979
6 · The paper itself

Abstract

Multiple large-scale tumor genomic profiling efforts have been undertaken in osteosarcoma, however, little is known about the spatial and temporal intratumor heterogeneity and how it may drive treatment resistance. We performed whole-genome sequencing of 37 tumor samples from eight patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a metastatic or relapse site. We identified subclonal copy number alterations in all but one patient. We observed that in five patients, a subclonal copy number clone from the primary tumor emerged and dominated at subsequent relapses.

Indexed as

clonal evolutionintratumor heterogeneityosteosarcomasomatic copy number alterationswhole-genome sequencing

Identifiers

PMID36711976
PMCPMC9881990
OpenAlexW4313637978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.